Shaq, Entrepreneurship, and Social Determinants of Health
Government policy should promote entrepreneurship to address health inequities. Shaq’s work with social determinants of health shows why.
Incentives
-
Read more: Shaq, Entrepreneurship, and Social Determinants of Health -
Read more: Tackling Salami Slicing and Indication Stacking in Orphan Drug Innovation Incentives Tackling Salami Slicing and Indication Stacking in Orphan Drug Innovation Incentives
Are the incentive mechanisms for orphan drug development working as they should?
-
Read more: Payments for COVID-19 Vaccination: Ethical and Legal Considerations Payments for COVID-19 Vaccination: Ethical and Legal Considerations
Should we pay people to receive COVID-19 vaccines? This post summarizes key ethical and legal considerations.
-
Read more: Authorize Emergency Vaccines for COVID-19, but Do It Well Authorize Emergency Vaccines for COVID-19, but Do It Well
We can simultaneously get COVID vaccines to those most at risk while minimizing harm to our ability to fully evaluate their safety and efficacy.
-
Read more: Why the Government Shouldn’t Pay People to Get Vaccinated Against COVID-19 Why the Government Shouldn’t Pay People to Get Vaccinated Against COVID-19
Paying for vaccination is dubious public health policy likely to backfire in terms of (re)building public trust in vaccines.
-
Read more: Opportunities and challenges for user-generated licensing models in gene-editing Opportunities and challenges for user-generated licensing models in gene-editing
By Timo Minssen, Esther van Zimmeren & Jakob Wested An earlier version of this contribution had been published in Life Science Intellectual Property Review (LSIPR). A voluntary pool or clearinghouse model may give rise to a robust commercial ecosystem for CRISPR and could include special provisions for royalty-free research use by academics. Hence, there may be a path through…
-
Read more: Will the EPO’s Enlarged Board of Appeal step into the CRISPR patent battle? Will the EPO’s Enlarged Board of Appeal step into the CRISPR patent battle?
By Jakob Wested, Timo Minssen & Esther van Zimmeren Another version of this contribution has been published in Life Science Intellectual Property Review (LSIPR). The Broad Institute is facing a formidable task in defending the revoked CRISPR patent claims in their pending appeal at the European Patent Office (EPO). Ultimately, some of the issues might still be referred…
-
Read more: Innovation Gaps on Life Science Frontiers Innovation Gaps on Life Science Frontiers
By Timo Minssen Join us in wonderful Copenhagen at our CeBIL Kick-Off Conference: ”Innovation Gaps on Life Science Frontiers? From Antimicrobial Resistance & the Bad Bugs to New Uses, AI & the Black Box”. The Conference marks the start of the Novo Nordisk Foundation’s Collaborative Research Programme in Biomedical Innovation Law which is carried out…
-
Read more: Copenhagen Conference: Legal Perspectives on Synthetic Biology and Gene Editing Copenhagen Conference: Legal Perspectives on Synthetic Biology and Gene Editing
Join us at the Centre for Information and Innovation Law (CIIR) Faculty of Law, University of Copenhagen on 20 November, 2017 to discuss Legal Perspectives on Synthetic Biology and Gene Editing. CALL FOR PAPERS Emerging technologies in Synthetic Biology and Gene Editing offer incredible opportunities and promising solutions to some of the most urgent challenges faced by…
-
Read more: Sequenom vs. Ariosa and international approaches to the patent eligibility of biomedical innovation Sequenom vs. Ariosa and international approaches to the patent eligibility of biomedical innovation
By Timo Minssen With a potential petition for writ of certiorari in the Sequenom v. Ariosa case approaching, it appears as if the US Supreme Court will once again have to consider crucial patent eligibility questions with a great significance for biomedical innovation and diagnostic methods. The claims at issue (see U.S. Patent No. 6,258,540 ) are directed to methods of genetic testing by detecting and…